JPRN-UMIN000008425尚未招募2 期
Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer - AVIRIX study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.History of severe allergy 2.Pregnant or lactating women or women of childbearing potential 3.Severe infection disease 4.HBsAg(+) or HBV-DNA(+) 5.Previous history of hemoptysis or evidence of bleeding diathesis or coagulopathy 6. Metastases to the CNS 7. Complication of inflammation or active gastrointestinal 8. Non-healing wound 9. anti-platelets therapy 10. History of thrombosis or cerebrovascular disorder 11. Uncontrolled high blood pressure 12. Serious heart disease 13. Uncontrolled diarrhea 14.Paresis of intestine or intestinal obstruction 15.Interstitial pneumonitis 16.Serious peritoneal fluid and pericardial fluid 17.Multiple primary cancer which heals within five years 18. receiving atazanavir sulfate 19. requiring steroid drug 20.Have the homo and double heterozygote of *6,*28. 21. Other conditions not suitable for this study
研究者
相似试验
已完成
不适用
Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancerJPRN-UMIN000008668Kitasato university school of medicine38
已完成
不适用
Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer -Beyond Progression Disease of capecitabine and bebacizumabColorectal CancerJPRN-UMIN000006877Gunma University Graduate School30
招募中
2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancerJPRN-UMIN000011679Chubu Clinical Oncology Group25
已完成
2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancernresectable metastatic or recurrent colorectal cancerJPRN-UMIN000011552Chubu Clinical Oncology Group (CCOG)25
进行中（未招募）
不适用
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE